In this report we highlight various aspects of the market for medicines in the U.S—spanning aggregate spending, key medicine categories, volumes, patient cost exposure, as well as our outlook to 2021. The report seeks to provide appropriate context and perspective around the complex factors that drive the level of spending on medicines and their role in our healthcare system.

Over the past decade, there has been a paradigm shift in the treatment of cancer, driven by advances in personalized medicine and immuno-oncology. In this report, we share our perspective on some of the trends observed in 2016, including impact on cancer outcomes, the redefinition of many cancers, availability and costs of oncology therapeutics and complexity in cancer treatments.

对2016年罕见病药物的研发管线进行了分析，对药物的名称，药物研发单位，药物适应症，药物研发阶段进行了深入的分析。

Explore the vaccines in development by drug name, sponsor, indication and development phase. There are over 250 vaccines currently in development.、

对2016年全球疫苗药物的研发管线进行了分析，对疫苗名称，疫苗研发机构，疫苗适应证进行了深入的分析。

目前在肿瘤免疫治疗药物研发的研发管线中，有超过248个免疫治疗药物处于在研状态。该报告对研发管线中的药物进行了分析和总结。

2015年美国PhRMA发布了《MEDICINES IN DEVELOPMENT FOR CANCER》，按照癌症药物的不同适应症，对800多个处于临床研究不同阶段的癌症药物进行了详细的分析。本报告对800多个处于临床的癌症药物，详细阐述了药物名称、研发公司、适应症及研发阶段。

2015年美国PhRMA发布了《MEDICINES IN DEVELOPMENT FOR CANCER》，按照癌症药物的不同适应症，对800多个处于临床研究不同阶段的癌症药物进行了详细的分析。

2015年美国制药商协会发布了《Researching Alzheimer’s Medicines ：Setbacks and Stepping Stones Summer 2015》。在报告中简要的总结了目前老年痴呆药物的治疗现状、研发现状已经存在的问题和挑战。